The FDA issues an emergency use authorization for Impella heart pumps to provide discharge therapy to COVID-19 patients.
DANVERS, Mass.- (BUSINESS WIRE) -- The United States Food and Drug Administration (FDA) has issued an emergency use authorization (US) for heart pumps Left ventricular assistance pump and offer left ventricular discharge and support to patients with COVID-19 who are in treatment with extracorporeal membrane oxygenation (ECMO) and develop pulmonary edema or myocarditis.
Impella bombs are manufactured by Abiomed (NASDAQ: ABMD).
COVID-19 causes widespread inflammation that can cause damage to the lungs and heart.
The statement in the original language is the official and authorized version of the statement.
Translation is only a tool and should be compared to the original language text, which is the only version of the text that has legal validity.